
    
      This is an observational, multicenter study in patients treated with nivolumab for the
      approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the
      United States (US). Targeted countries in the EU for study participation include Austria,
      Belgium, France, Germany, Italy, Spain, Czech Republic, Hungary, Poland and the United
      Kingdom (UK). Study objectives are to assess the safety experience, survival, adverse event
      management, and outcomes of adverse events associated with nivolumab in routine oncology care
      facilities. The study will be started in 2016, and data collection will be continued until
      March 2024.
    
  